Target Information

Target General Infomation
Target ID
T62945
Former ID
TTDI01618
Target Name
Voltage-dependent calcium channel
Target Type
Successful
Disease Muscle spasm [ICD10: M62.838]
Parkinson's disease [ICD9: 332; ICD10: G20]
Drugs and Mode of Action
Drug(s) Tolperisone Drug Info Approved Muscle spasm [551871]
Eperisone Drug Info Phase 3 Muscle spasm [524606]
GCC-1290K Drug Info Phase 1 Parkinson's disease [530122]
Modulator Eperisone Drug Info [530122], [533095]
GCC-1290K Drug Info [530122]
Tolperisone Drug Info [527704], [530122]
References
Ref 524606ClinicalTrials.gov (NCT02040415) Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients. U.S. National Institutes of Health.
Ref 530122Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 527704Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. Epub 2005 Aug 26.
Ref 530122Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
Ref 533095Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.